The $100B Weight Loss Drug Market Loses Steam As Euphoria Fades
Like a dieter’s initial enthusiasm giving way to reality, the weight loss drug market has hit a plateau. Novo Nordisk and Eli Lilly have seen their market values shrink as disappointing trial results and lower-than-expected sales have dampened investor excitement for the once-hot obesity drug sector. This shift has resulted in steep valuation drops and increased scrutiny over the market’s future prospects.
- In the past six months, Novo Nordisk’s shares plunged 37% after its next-generation obesity drug, CagriSema, missed its target weight loss goal — wiping out $90B in market value.
- Similarly, Eli Lilly’s Q4 sales fell short of expectations, while its shares dropped 14% after Mounjaro and Zepbound missed their targets by $0.9B and $0.3B, respectively.
Reality check: The sector’s future remains clouded by manufacturing constraints, pricing pressures, and political uncertainties. While Eli Lilly still projects 28-35% sales growth for 2025, investors are increasingly skeptical about the $100B+ market size analysts predict by the decade’s end. As Eli Lilly’s David Ricks noted, “The easy money has been made,” — potentially indicating the market will grapple with the weight of whether these revolutionary drugs can live up to their astronomical expectations.
